drugset / Trial / NCT04249713
An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
NaSingle-groupOpen-labelBasic science
Summary
Phase 0 Study of an alternative dosing interval of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.
Timeline
- Start
- 2020-02-03
- Primary completion
- 2020-07
- Completion
- 2020-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |